Passage Bio, Inc.

Good morning, and welcome to the Passage Bio Third Quarter 2020 Financial and Operating Results Conference Call. At this time, all participants are in the listen-only mode. Following the following remarks, we will open the call up for your questions. Please be advised that this call is being recorded at the company's request. At this time, I'd like to turn the call over to Zoe Mehta. Zoe, please proceed.

Thank you, Operator. This morning, we issued a press release that outlines the topics we plan to discuss today. This release is available on the PassageBio website at investors.passagebio.com under the News and Events section. On today's call, Bruce Goldsmith, President and Chief Executive Officer, and Rich Morris, Chief Financial Officer, will review our third quarter 2020 financial results and discuss recent business highlights. Gary Romano, our Chief Medical Officer, and Jill Quigley, our Chief Operating Officer, will also be available for the Q&A portion of the call. Before we begin, please note that today's call may include a number of forward-looking statements, including, but not limited to comments on, our expectations about timing and execution of anticipated milestones, including the resolution of FDA feedback on INDs, the initiation of clinical trials, and the availability of clinical data from such trials, our expectations about our collaborators' and partners' ability to execute key initiatives, the ability of our lead product candidates to treat the underlying causes of their respective target monogenetic CNS disorder, manufacturing plans and strategies, trends with respect to financial performance and cash flows, the company's ability to fund research and development programs, impacts of the COVID-19 pandemic on the company's operation, and its ability to manage costs along with uses of cash and other matters. These forward-looking statements are based on assumptions that are subject to risks and uncertainties that could cause the company's actual results to differ significantly from those suggested by these statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. Please refer to the company's filings with the SEC for information concerning risk factors that could cause its actual results to differ materially from expectations, including any forward-looking statements made on this call. Except as required by law, the company disclaims any obligation to publicly update or revise any forward-looking statements to account for or reflect events or circumstances that occur after this call. It is now my pleasure to pass the call over to CEO, Bruce Goldsmith. Bruce?

Thanks, Zoe, and thank you all for joining us this morning. This year, we have continued to make significant strides in strengthening our operations in anticipation of having our three lead programs in clinical development next year. Powering our progress has been our growing team of talented leaders dedicated to achieving our mission of providing life-transforming gene therapies for patients with rare monogenic CNS diseases, all while building lasting relationships with the communities we serve. The foundation of the company, as you know, is based on our strategic partner, Dr. James Wilson, who leads the preeminent University of Pennsylvania's gene therapy program, GTP. This partnership provides us with unrivaled access to cutting-edge research and clinical candidates that are the result of world-class expertise and resources capable of translating science into optimal gene therapies with a higher probability of technical and regulatory success. On today's call, we'll mostly focus on where we stand with our three lead programs in GM1 gangliosidosis, frontotemporal dementia, and Crab A disease. We also have three preclinical programs in earlier stages of development in amyotrophic lateral sclerosis, or ALS, metachromatic leukodystrophy, or MLD, and Charcot-Marie-Tooth disease, type 2A, or CN2A. In addition, through our GCP partnership, we have the option to license a total of 17 programs focused on rare monogenic disorders of CNS, making our potential pipeline quite robust We are also well-funded to support our operations, and this financial flexibility is another key asset as we advance our initial three programs into clinical development. Today, I am excited to review some of our recent accomplishments, particularly across patient identification, clinical site preparedness, and manufacturing readiness. I will start with an update on our lead program, PBGMO1. As a reminder, GM1 is a rare monogenic recessive lysosomal storage disease caused by mutations in the GLB1 gene encoding the enzyme beta-galactosidase. We are targeting the infantile form of the disease, which is the most severe, with a rapid disease course and no current treatment options. Our lead program, PVGM01, is a best-in-class gene therapy utilizing a next-generation proprietary AAVHU68 capsid and optimize gene expression cassette to deliver a GLB1 transgene encoding beta-gal to increase beta-gal enzyme activity in the brain and peripheral tissues. During our second quarter earnings call, we announced that FDA had placed our IMD on PD-GMO1 on clinical hold due to questions concerning the biocompatibility of our proposed intercisternamagna, or ICM, delivery device. As previously disclosed, we have now received our official letter from FDA confirming that the hold was due solely to these biocompatibility concerns. Based on guidance from FDA, we are conducting biocompatibility risk assessments and testing to resolve their questions as quickly as possible. We continue to engage with the agency and remain confident that we will be able to adequately address any concerns, and we continue to expect to receive IMD clearance. Because of our work to satisfy FDA's biocompatibility requirements, we now expect to initiate the Phase 1-2 clinical trial in the first quarter of 2021 and to report initial safety and biomarker data mid-2021. While we work toward R&D clearance, our clinical trial preparations remain on track. As we discussed on our previous call, we have aligned with the agency on an updated trial design. As a reminder, this trial will be an open-label dose escalation study of PBGM01 administered by a single injection into the intercisterna magna in pediatric subjects with early and late infantile GM1. For the dose escalation portion of the trial, we have changed the design to specifically study early and late infantile patients in separate smaller cohorts. We will now be enrolling a total of four cohorts of two patients each. with separate dose escalation cohorts for late-onset infantile GM1 and early-onset infantile GM1. Because safety of our patients is our top priority, in addition to the trial amendments, we have also implemented approaches for the GM1 study that address the challenges of the current COVID-19 environment. Such approaches include remote clinical assessments, structured video capture of study subjects in the home, and concierge services through third-party vendors to facilitate travel due to increased burdens and restrictions. We believe these measures will provide patient support while also maintaining the rigor of our clinical trials and our ability to provide this potentially life-altering therapy to patients. As we have discussed, GM-1 is a devastating disease that impacts patients worldwide, and we are dedicated to serving at-aid patients in the U.S., and across additional demographics and geographies. Clinical supply for the Phase I-II trial has been manufactured and is ready for dosing. And in addition to submitting our IND to FDA, we have also filed for clinical trial approvals in countries outside of the U.S. We are pleased with our overall progress in activating clinical sites around the world. The need for an effective therapy is underscored by our recent orphan disease designation in Europe, granted to PBGMO1 by the European Commission in October. PBGMO1 previously received orphan drug and rare pediatric disease designations in the U.S. We look forward to working with these and other government agencies to fill the treatment gap for GM1 around the globe. Our aim is to keep patients at the center of PBGMO1's development and to work with families and physicians to drive the best possible outcome for patients. As we prepare for clinical site activations, we are ramping up patient identification and education efforts, starting with our recently announced partnership with Invitae, a leading medical genetic testing company, to increase genetic testing and support early identification of GM1 through a program called Detect Lysosomal Storage Disorders. The Detect LSDs program offers free genetic testing and counseling to encourage earlier diagnosis of lysosomal storage diseases like GM1. Additionally, Invitae will be reaching out to healthcare providers who have patients that have tested positive for GM1 to provide educational and clinical trial information. We believe this partnership will be a crucial resource, not only for our clinical program, but also for the patient community more broadly, as we aim to shorten the timeline for reliable diagnosis, treatment, and ultimately halting the progression of this disorder. We continue to engage with patient advocacy groups on important initiatives, such as newborn screening. Currently, we are sponsoring the New York Screen Plus pilot program, which will offer newborn screening for rare diseases, including GM1, to 150 to 175,000 ethnically diverse babies in eight hospitals across the state of New York. Additionally, we are involved in other meetings and initiatives sponsored by our advocacy partners to determine ways to support further adoption of newborn screening. Preclinical data, including recently published data in the peer-reviewed journal Human Gene Therapy, continue to support the potential of PBGMO1 as a treatment for the underlying cause of GM1. In a murine model, the data showed that by increasing beta-gal activity in the brain and peripheral tissues, PBGMO1 was able to reduce neuronal loisosomal storage lesions improve neurological function, and increase survival. This data is encouraging and suggests immense potential for GM1 patients. We are excited to advance PB-GMO1 toward clinical development and begin dosing patients. Based on the support of preclinical data, physician and advocacy engagement, and productive interactions with FDA, we look forward to getting this trial started as soon as possible. As for our other lead programs, PBFTO2 for FTD and PBKRO3 for Crab A disease, we plan to file INDs for both once we receive FDA clearance for our GM1 program. Based on our current timelines, we are preparing for Phase 1-2 clinical trial initiations for PBFTO2 and PBKRO3 in the first half of next year. As we finalize the protocols of our FTD and Crab A clinical trial programs, We plan to incorporate feedback from FDA regarding our GM1 program as applicable in order to design the safest, most efficient trials possible for these two indications. As a reminder, PD-FTO2 is a gene therapy that utilizes an AAV1 vector to deliver to the brain a functional granulin gene encoding the progranulin protein, a complex and highly conserved protein thought to have multiple roles in cell biology and inflammation. In September, we announced the publication in a peer-reviewed journal of preclinical data from our partners at Penn's GTP. In mass data, a single administration of an optimized AAV1-GRN vector of PVF-T02 showed the greatest increase in CSF progranular levels when compared to two other AAV vectors, reaching more than 50-fold the normal human CSF progranular levels. The data showed that AAV1-GRN also appeared to demonstrate extensive transduction of the ependymal cells, which line the ventricles of the brain and are involved in the production of CSF. Following these increased progranular levels, subjects showed reduced lysosomal storage lesions, normalized lysosomal enzyme expression, and corrected microgliosis. In addition to demonstrating the ability of PBFTO2 to drive key biomarker results, Data from the study also supported our ICM route of delivery, which was shown to be well tolerated and minimally invasive. Our use of the AAV1 capsid in ICM's route of delivery is a result of rigorous preclinical development work conducted by our partners at GTP, illustrating again the benefits of our core business model of unparalleled access to cutting-edge science and research. We are also preparing our third program, PVKRO3, for a Phase I-II trial for the treatment of Krabbe disease, a rare and often life-threatening lysosomal storage disease that results in progressive damage to both the brain and peripheral nervous system. As we discussed in detail on our last call, data from preclinical models shows that PVKRO3, which utilizes the AAVHE68 capsid to deliver a functional GalC gene, increased GalC enzyme activity reduced cytosine accumulation, and restored myelin, leading to a phenotypic correction and increased survival in a naturally occurring canine model. We recently announced that FDA granted orphan drug and rare pediatric disease designations to PbKRO3 for Krabbe disease, further suggesting its potential and emphasizing the need for effective treatment options. We are encouraged that FDA recognizes the critical unmet need in this patient population and we believe that PDK-RO3 has the potential to be a life-altering therapy that can address the underlying cause of disease. We look forward to initiating our Phase I-II trial in the first half of 2021. Finally, turning to our earlier stage pipeline, we continue to progress our earlier programs for the treatment of MLD, ALS, and CMT2A, and we look forward to providing further updates as these programs move closer to clinical development. Beyond our clinical programs, we are also expanding our operational capabilities and are excited to announce the completion of our dedicated GMP manufacturing suite at Catalan. Construction of the suite is now complete and has undergone qualifications for GMP manufacturing readiness. We plan to initiate manufacturing activities at our dedicated suite this quarter, and we will be able to meet production requirements for our lead pipeline products through early commercialization. Manufacturing capacity has been a key tenet of our strategy since launching the company. This milestone marks important progress towards securing control of our supply chain, which we believe will set us up for both clinical and commercial success. To support our continued growth and upcoming trial initiations, we continue to make key hires across our clinical, regulatory, manufacturing, and corporate teams. I am delighted Passage Bio's mission has resonated with so many talented individuals, and we feel we are assembling the right group of dedicated, experienced leaders to accomplish our goals. And with that, I will turn the call over to Rich to give a financial update.

Thank you, Bruce. As we reported in our press release this morning, we ended the quarter with cash, cash equivalents, and marketable securities of approximately $336 million. as compared to $159 million as of December 31st, 2019. We expect our current cash balance to fund our operations into 2023. R&D expenses were $20.8 million for the quarter ended September 30th, compared to $10.4 million for the same quarter in 2019. The increase was primarily due to an increase of $8.3 million in clinical manufacturing costs and a $1.9 million increase in clinical development costs as we prepare for our clinical trials to begin in early 2021. These increases were offset by a $4.3 million decrease in preclinical research and development costs incurred as we finalized work associated with our lead indications in preparation for IND filings. We also had a $4.5 million increase in personnel-related costs, including share-based compensation, due to increases in employee headcount in the R&D function. G&A expenses were $7.8 million for the quarter ended September 30th compared to $1.2 million for the same quarter in 2019. The increase was primarily due to a $4.4 million increase in personnel-related and share-based compensation expense due to increases in employee headcount. Our professional fees and facility costs also increased by $.6 million and $1.6 million, respectively, as we expanded our operations to support our research and development efforts. Net loss was $28.5 million for the third quarter 2020. compared to $11.4 million in the same quarter of 2019. Net loss per basic and diluted share was 63 cents in the third quarter of 2020, compared to a $2.02 net loss per basic and diluted share in the third quarter of 2019. Now, I will turn the call back to Bruce for closing remarks.

Thanks, Rich. As we are close to the end of this year, I want to take a moment to reflect on our progress throughout 2020. This year, we expanded the foundation of the company as we continue to prepare the clinical stage development of three promising pipeline assets next year, taking us closer to our goal of offering innovative, safe, and effective therapies to patients who currently have limited or no treatment options. As I shared earlier, we are engaging with FDA to resolve their questions regarding device biocompatibility. We anticipate dosing our first patient in the Phase 1-2 trial of PBG-M01 in the first quarter of 2021. We continue to prepare our clinical sites for dosing in both the U.S. and abroad, and are undergoing measures to support patient safety amidst the evolving COVID-19 pandemic. We expect to report initial 30-day biomarker and safety data for the first cohort of late-onset infantile GM1 patients in mid-2021. We also remain on track to initiate phase 1-2 trials for our FTD and CRAB-A programs in the first half of 2021. As I mentioned earlier, we continue to expand our clinical manufacturing and operations teams to support these programs, along with the future development of additional pipeline candidates, all with the goal of transforming the lives of patients suffering from serious, life-threatening, rare monogenic central nervous system diseases. The reason we have been able to be so productive despite a challenging year is because of our talented, committed team of employees at Passage Bio. I'd like to take this opportunity to recognize and thank them for their flexibility, hard work, and diligence as we head into the final months of this year. It's because of them that we are well prepared to take on what promises to be a milestone filled year in 2021. At this time, we'd like to open the call up for your questions. Operator?

Thank you, sir. We will now take any questions you may have. If you have a question, press star 1 and you'll be put into the queue. If you'd like to remove yourself in the queue, please press the pound key. The first question comes from Anupam Rama from JP Morgan. Please go ahead.

Hey, guys. Thanks so much for taking the question. Just a quick one from me. For the in vitae collaboration with Krabbe also being a lexosomal storage disorder, are there plans ultimately to include this indication as part of the collaboration, you know, facilitating genetic testing and patient identification? If I could squeeze one more in on the biocompatibility risk assessments and testing of the ICM device, maybe any more color on the final gating factors kind of completing this and and discussions with the FDA. Thanks so much.

This is Gary. We may have lost Bruce's connection. Oh, sorry. Okay.

No, Gary. Apologies. Autopom, thanks very much. I was on double mute as opposed to single mute at that time. So thanks for your question, and thanks for joining the call. Apologies for the delay. So I'll take the second question, and then I'll turn it over to Jill for a discussion on the EVTA calibration and other approaches we're taking on patient identification. So, yeah, we're essentially... The gating items and the discussions with the FDA are really completing some of the testing and finalizing the reports and essentially moving forward with the final risk assessment. And that's been based on an interactive discussion with the FDA since receiving a letter earlier this year and simply completing those tests. And we had indicated back in, I think, September and August, that those were probably going to take about seven to eight weeks. And we're generally on that timeline and still on track for our initiation of the clinical study in the first quarter of next year. And that's for GM1. And then we'll file, as we said, for FTD and Krabbe sequentially after that. So initiation of those studies should be in the first half of next year. So overall, still moving forward with the initial plans, and the gating items are really just finalizing all of those tests and risk assessment. Jill?

Sure. So, Annapon, that's a great question about the newborn screening initiative for Crabbe. Currently, Crabbe is not included on New York Screen Plus, but Crabbe, as you know, has newborn screening pilot in-states Across multiple states, I think there were up to about nine states that are now screening for CRABE. One of the reasons we initially focused on supporting the inclusion of GM1 for New York Screen Plus is because there are no states doing any newborn screening for GM1 currently. And certainly, as the program progresses, we can consider adding CRABE, although there are multiple states that have pilot programs already for that.

Yeah, and the same approach for NVTA as well, which is that, you know, the lysosomal storage disease detect program is certainly able to be expanded as we move forward.

Thanks so much for taking our questions.

Thank you. Our next question comes from the line of Salveen Richter. Go ahead.

Hi. This is Sonia on for Salveen. You recently announced a partnership with NVTA towards the goal of increasing patient identification efforts in GM1. Could you comment on the number of patients you would expect to identify from the partnership? And then have you had discussions with the FDA? Have your discussions with the FDA impacted your filing plans for either of the diseases on GM1?

Yes, so I taught the first part and that was on Invitae. So the way that we think about this is Invitae and also the combination of that with pilot programs like the New York Screen Plus is to do two things. One is to identify patients and essentially get the patients that are coded and have a genetic screen and are identified with GM1. Right now, the incidence is predicted to be about 0.5 in 100,000 live births, which is really just around, you know, 50 patients potentially per year, 50 children. But we also recognize that the underdiagnosis of a disease that does not have a standardized genetic screen that is in, that is being used in practice may increase the identification of the disease. So we're partnering with NVTA on two aspects. One is to, as testing is needed, to allow for free testing, which should hopefully lower an economic barrier for the potential screening of GM1, which may increase both the incidence and the detection of that incidence. And then the second part is for those patients who have already been identified there's an educational and awareness campaign to talk about clinical studies that are available. So in all of those, the idea, as well as the New York Screen Plus, is to raise awareness and potential identification of the patients. So hopefully that all of the actual incident patient population is eventually diagnosed and brought into potential therapy. So we don't have a specific number because the gap right now that exists is for those patients who may have the disease but are not aware. And in Vitae's program, as well as partnerships like New York Screen Plus and partnerships with advocacy groups, are hoping to increase the awareness and the identification of patients. And could you repeat your second question?

Yeah, yeah. So you noted the plan to incorporate feedback from FDA on GM1 as applicable for CRAB and FDD indications. So we were just wondering how those discussions with the FDA have impacted your filing plans for other diseases.

Sure. If you don't mind, maybe I'll turn it over to Gary to talk about the filing plans for FTD and Krabbe.

Sure. Thanks, Bruce. Yep, thanks. So thanks for the question. We are still planning to submit our INDs for FTD and Krabbe. in the early first quarter of next year, first half of next year. So again, as Bruce mentioned, this is going to follow the FDA getting off the clinical hold from the GM-1 program. So immediately following getting off the hold, we intend to move forward with the other ID submissions. As Bruce mentioned, that should happen towards the end of this year, beginning of next. Thank you. Thank you.

Thank you. As a reminder, to ask a question, you would need to press star one on your telephone. To withdraw your question, please press the pound key. I show our next question comes from the line of Yaron Weber from Cowan. Please go ahead.

Hi, guys. This is Brendan on for your own. Congrats to the quarter. Thanks again for taking the questions. Just a couple quick ones from us. I guess first, just really kind of wanted to get a sense of where recruitment stands for these programs. Obviously, you can't treat with the hold in place, but have you been able to kind of recruit some patients for any of these, I suppose, particularly for GM1s? Is there maybe a bit of a bolus there ready for when the hold is lifted?

Yeah, I'll start, and then I'll turn it over to Gary. I mean, you know, Gary can talk about maybe some of the patient recruitment efforts where we're undertaking in the connections with sites. But I do want to mention that one of our approaches has always been that if a patient is in need of therapy, they should get therapy. So we're, you know, while sites are certainly engaged, if there are other alternatives, we're really trying to be patient-focused here. And since there has been uncertainty, obviously, with our timelines, even though we have a projected timeline, we've been very careful not to, ask sites to hold patients, for example, because as you know, these patients, GM1, Krabbe, and patients with FTD are in a very severe state. So we've been very patient-focused in kind of our approach and know that once our therapies, the clinical holds are, the clinical hold is lifted and the further INDs are filed, we'll obviously be then focused on patient recruitment. You know, having said that, we've certainly been in touch with sites and physicians and patient advocacy groups, and maybe, Gary, you can offer some additional commentary about how the reaction is in patients that are interested in participating in the study, or families, we should say.

Yeah, thanks, Bruce. Yeah, so we've been working with centers of excellence around the world for GM1. So this includes North America, Europe, South America, Middle East. These are the centers that get referrals for these patients. throughout the world. So we're really – our intention is to be able to bring patients from different demographics and geographies as quickly as we can into the study. We are – as Bruce mentioned, we are moving forward with these filings to open sites across the world, and we expect that we will have sites ready to enroll as soon as we come off the clinical hold, which we anticipate to be right around the early 2021. Yeah, so that, you know, we are anticipating that there's been a lot of enthusiasm from all these sites, and as we just mentioned, we're not holding patients in a queue at this point, but we know the patients are out there, and our trial will be well positioned to enroll. Okay. Thanks very much, guys.

Thank you. And I'm showing no further questions in the queue at this time. Ladies and gentlemen, thank you for participating in today's conference. This concludes your program, and you may now disconnect. Everyone have a great day.